SS-31 (Elamipretide): A Research Review of Mitochondrial Targeting, Cardiolipin Binding, and Bioenergetics

Peptides R Us provides premium research peptides developed for laboratories, researchers, and qualified professionals who demand purity, accuracy, and consistency. Every product is handled with strict quality-focused standards to support reliable research outcomes and professional laboratory use.

SS-31—also published as elamipretide, MTP-131, and historically Bendavia—is one of the most closely studied mitochondria-targeted tetrapeptides in the literature. It does not act like a typical cell-surface signaling peptide. Instead, it concentrates at the inner mitochondrial membrane and interacts with cardiolipin, a phospholipid that organizes cristae structure and electron-transport complexes. That design has made SS-31 a standard tool compound in mitochondrial dysfunction, aging-bioenergetics, ischemia-reperfusion, and cardiolipin-biology models.

Important distinction for researchers: an FDA-approved pharmaceutical product (Forzinity / elamipretide) exists for a narrow Barth syndrome indication. Research-grade SS-31 sold for laboratory work is not that drug, is not interchangeable with it, and is not for human or veterinary use.

What SS-31 Is

SS-31 is a synthetic aromatic-cationic tetrapeptide from the Szeto–Schiller (SS) series, developed by Hazel Szeto and Peter Schiller.

The alternating cationic/aromatic motif is load-bearing. D-arginine and lysine provide electrostatic interaction with cardiolipin’s anionic phosphate head groups. Dimethyltyrosine and phenylalanine support hydrophobic contact with acyl chains. The D-amino acid and C-terminal amide improve stability relative to a conventional L-peptide.

Unlike many mitochondria-directed probes that rely on membrane potential to accumulate, SS-31 can localize to the inner membrane even when potential is impaired. That property matters in stressed or diseased mitochondrial models, where the usual electrochemical driving force is reduced.

How SS-31 Works in Research Models

Early papers described SS-31 as a mitochondria-targeted antioxidant. Later work refined that picture. Contemporary reviews argue that ROS reduction is largely a consequence of better membrane organization and electron flow, not simple radical scavenging.

Cardiolipin is the address

Cardiolipin is almost exclusive to the inner mitochondrial membrane. It supports:

• Cristae curvature and surface area for oxidative phosphorylation
• Assembly of respiratory supercomplexes
• Cytochrome c positioning between Complex III and Complex IV
• Membrane dynamics, including fission/fusion and apoptotic signaling

When cardiolipin is oxidized, depleted, or poorly remodeled, electron leak rises, peroxidase activity of cytochrome c can increase, and ATP production falls.

SS-31 binds cardiolipin through electrostatic and hydrophobic contacts. That interaction has been corroborated by fluorescence spectroscopy, isothermal titration calorimetry, NMR, and membrane-biophysics studies.

Downstream effects reported in the literature

Published mechanisms cluster around four linked observations:

1. Cristae and membrane organization. SS-31 can improve cristae architecture and modulate cardiolipin packing / aggregation in model membranes.
2. Cytochrome c function. The SS-31–cardiolipin complex can limit cardiolipin-driven conversion of cytochrome c into a peroxidase while supporting its electron-carrier role.
3. Electron transport and ATP synthesis. Studies report improved state-3 respiration, coupling (P/O), respiratory control, and ATP output in stressed mitochondria.
4. Protein interactome. Cross-linking / mass spectrometry work shows SS-31 in proximity to cardiolipin-binding proteins in oxidative phosphorylation and 2-oxoglutarate metabolism, including ANT1 and components of the ATP synthasome. In aged muscle and heart models, this has been linked to reduced proton leak and improved ADP sensitivity.

In short: the peptide is better described as a cardiolipin-targeted membrane modulator than as a generic antioxidant.

Research Areas Where SS-31 Is Used

Barth syndrome and cardiolipin remodeling

Barth syndrome is caused by TAFAZZIN mutations that impair cardiolipin remodeling. That makes it the closest clinical match to SS-31’s proposed mechanism.

TAZPOWER was a small Phase 2/3 crossover study (12 patients, 40 mg subcutaneous daily). The 12-week blinded phase did not meet co-primary endpoints (6-minute walk test and fatigue score). Longer open-label extension data reported functional gains in walking distance, fatigue scores, and selected cardiac measures. Those longer-term datasets, plus additional supporting evidence, were part of the regulatory record that led to accelerated FDA approval of pharmaceutical elamipretide (Forzinity) in September 2025 to improve muscle strength in Barth syndrome patients weighing at least 30 kg.

For laboratory teams, the scientific lesson is specific: a cardiolipin binder is most coherent in models where cardiolipin itself is the lesion.

Primary mitochondrial myopathy

MMPOWER Phase 1/2 work suggested a short-term, dose-related signal on 6-minute walk distance after five days of intravenous dosing. The larger Phase 3 MMPOWER-3 trial (subcutaneous 40 mg daily for 24 weeks) did not meet co-primary endpoints of walk distance and fatigue versus placebo. Safety was generally acceptable; injection-site reactions were common.

That split—signal in Barth syndrome, miss in broader PMM—is useful for experimental design. Not every mitochondrial disease is a cardiolipin disease.

Aging muscle and cardiac bioenergetics

Preclinical work in aged mice is among the strongest mechanistic literature:

• Improved maximal ATP production and OXPHOS coupling in aged skeletal muscle
• Reduced age-related proton leak in cardiomyocytes
• Association with ANT1 and ATP-synthasome stabilization
• Improved ADP sensitivity through ANT-mediated uptake
• Partial reversal of age-related diastolic dysfunction after multi-week treatment

These studies treat SS-31 as a probe of modifiable mitochondrial quality, not as proof of a consumer “anti-aging” use.

Ischemia-reperfusion, neurodegeneration, and other stress models

SS-31 has been used in ischemia-reperfusion, doxorubicin toxicity, burn trauma, LPS-induced synaptic impairment, and various neurodegeneration models. Reported readouts include respiration, ROS emission, cristae ultrastructure, fusion/fission markers, and cell-survival endpoints. Results are model-dependent. A failed or mixed clinical program in dry AMD with geographic atrophy is a reminder that structural mitochondrial effects do not automatically translate into clinical endpoints.

How Researchers Should Read the Evidence

A careful review separates three layers:

1. Biophysical and cell/organelle data — cardiolipin binding, membrane effects, ETC organization. Relatively consistent.
2. Preclinical physiology — aged muscle/heart, ischemia, selected genetic models. Often positive, still context-specific.
3. Human trials — mixed. Strongest alignment where cardiolipin remodeling is the core defect (Barth). Broader mitochondrial myopathy and several other indications did not meet primary endpoints.

That is the opposite of hype. It is also why SS-31 remains scientifically interesting: the mechanism predicts where it should work, and the trial record has partly confirmed that prediction.

Laboratory Handling Notes (Research Use Only)

Research-grade SS-31 is typically supplied as a lyophilized powder. Standard peptide practice applies:

• Confirm identity and purity (HPLC plus mass spectrometry), not purity alone
• Match the COA lot number to the vial
• Review endotoxin data when the assay is cell-based
• Reconstitute with an appropriate sterile solvent for the protocol
• Aliquot to limit freeze–thaw cycles
• Store lyophilized material cold and dry per the lot documentation

Research-grade material is not manufactured or labeled as the approved Barth syndrome drug. Do not treat catalog specifications, clinical-trial milligram figures, or Forzinity labeling as instructions for unapproved use.

Why Quality Matters for Mitochondrial Work

Mitochondrial assays are sensitive to impurities, endotoxin, and incorrect identity. A chromatogram that shows “high purity” without MS confirmation does not prove the peak is SS-31. Dimethyltyrosine content, D-arginine stereochemistry, and C-terminal amidation are part of the molecule’s targeting logic. Substitution or truncated sequences can change membrane behavior.

Peptides R Us focuses on research peptides for laboratories and qualified professionals who need consistent, well-documented material. Strict quality-focused handling is intended to support reproducible experimental outcomes—not clinical administration.

Frequently Asked Questions

Is SS-31 the same as elamipretide?
Yes. SS-31 is the research code. Elamipretide is the INN. MTP-131 and Bendavia are older names for the same tetrapeptide (CAS 736992-21-5).

Is research SS-31 the same as Forzinity?
No. Forzinity is an approved prescription product for a defined Barth syndrome indication. Research peptides are laboratory reagents and are not for human use.

Does SS-31 only scavenge ROS?
No. Current mechanistic papers emphasize cardiolipin binding, membrane organization, cytochrome c function, and interactions with OXPHOS-related proteins. Lower ROS is often secondary to improved electron handling.

Why did some trials succeed and others fail?
Barth syndrome is a cardiolipin-remodeling disease. Broader primary mitochondrial myopathy is mechanistically more heterogeneous. A cardiolipin-targeted peptide is not a universal mitochondrial drug.

What should a lab verify before an experiment?
Lot-matched COA, HPLC purity, MS identity, net peptide content, and endotoxin where relevant.

Research Disclaimer

This article is an educational research review for laboratories, investigators, and qualified professionals. It is not medical advice, not a dosing guide, and not a claim that research-grade SS-31 treats, cures, or prevents any disease. SS-31 / elamipretide research materials from Peptides R Us are intended solely for in vitro and authorized laboratory research. Not for human or veterinary consumption.